Fast Five Quiz: Type 2 Diabetes and Obesity and Weight Management

Anne L. Peters, MD; Romesh Khardori, MD, PhD


February 22, 2023

Many patients with type 2 diabetes are unable to attain and maintain substantial weight loss, despite the clear benefits. Metformin, a biguanide drug, is typically recommended in an individual without risk factors for CVD/CVD/chronic kidney disease (CKD) and/or heart failure (HF) when lifestyle modifications, such as diet and exercise, have not been effective at lowering hyperglycemia. Metformin is first-line therapy for obesity-induced diabetes. Along with reducing blood sugar, metformin causes neither weight gain nor hypoglycemia. Some studies have shown that cardiovascular mortality may be lower in patients prescribed metformin compared with sulfonylureas; however, large cardiovascular outcomes trials have been done with either agent.

Insulin, sulfonylureas, and thiazolidinediones are typically associated with weight gain.

Learn more about the pharmacologic therapy for type 2 diabetes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.